Genesis of derivative chromosome 9 deletions in chronic myeloid leukemia [1]

Genes Chromosomes and Cancer

Volumn 43, Issue 2, 2005, Pages 223-224

  Nacheva, E ^a   Reid, Alistair G ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL POPULATION; CHROMOSOME 9; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME IDENTIFICATION; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; LABORATORY DIAGNOSIS; LETTER; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 17644384489     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20163     Document Type: Letter

References (15)

1. Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW. 1998. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 92:2315-2321.
2. Chase A, Grand F, Zhang JG, Blackett N, Goldman J, Gordon M. 1997. Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization. Genes Chromosomes Cancer 18:246-253.
3. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, Trakhtenbrot L. 2001. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128:114-119.
4. de la Fuente J, Merx K, Steer FJ, Muller M, Szydlo RM, Maywald O, Berger U, Hehlmann R, Goldman JM, Cross NC, Melo JV, Hochhaus A. 2001. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 98:2879-2880.
5. Herens C, Tassin F, Lemaire V, Beguin Y, Collard E, Lampertz S, Croisiau C, Lecomte M, De Prijk B, Longree L, Koulischer L. 2000. Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 110:214-216.
6. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR. 2001. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98:1732-1738.
7. Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, Squire JA. 2001. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97:3581-3588.
8. Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P, Harousseau JL, Bataille R, Avet-Loiseau H. 2000. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 18:1533-1538.
9. Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, She CJ, Yoon SS, Shin HR, Kim Y, Cho HI. 2003. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes Chromosomes Cancer. 37:291-299.
10. Loncarevie IF, Romer J, Starke H, Heller A, Bleck C, Ziegler M, Fiedler W, Liehr T, Clement JH, Claussen U. 2002. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 34:193-200.
11. Muller C, Hennig E, Franke C, Krahl R, Leiblein S, Niederwieser D, Deininger MW. 2002. The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients. Cancer Genet Cytogenet 136:149-150.
12. Najfeld V. 2002. High performance of the BCR/ABL-extra sensitive (ES) probe for detection of der(9q) deletion in t(9;22)(q34;q11.2). Cancer Genet Cytogenet 132:171.
13. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. 2003. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukemia. Br J Haematol 121:419-427.
14. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR. 2000. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95:738-743.
15. Storlazzi CT, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, Rocchi M, Liso V. 2002. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 35:271-276.